12:48 PM EDT, 04/28/2025 (MT Newswires) -- TuHURA Biosciences ( HURA ) said Monday that updated results from Kineta's VISTA-101, a Phase I/II first-in-human study of KVA12123 alone and in combination with pembrolizumab in patients with advanced solid tumors, showed the therapy was generally safe and well tolerated, with no dose-limiting toxicities observed.

The company said KVA12123 also demonstrated a favorable pharmacokinetic and pharmacodynamic profile at all dose levels.

TuHURA entered a definitive agreement on Dec. 11, 2024, to acquire Kineta, including rights to KVA12123, for a combination of cash and shares. The deal, subject to closing conditions, is targeted to close in Q2.

TuHURA also presented results of its IFx-Hu2.0 therapy in patients with advanced treatment-refractory melanoma.

The company said that, following treatment with IFx-Hu2.0, three out of four heavily pre-treated patients with advanced melanoma who were resistant to anti-PD-1-based therapy showed clinically meaningful, durable anti-tumor responses after re-administration of a checkpoint inhibitor.

The first-in-human study of IFx-Hu2.0 also showed stimulation of an innate immune response, with increased T cell and B cell production in peripheral blood compared to tumor tissue, the company said.

The results were presented at the American Association for Cancer Research annual meeting in Chicago, Illinois.

Shares of TuHURA were down nearly 6% in recent trading.

Price: 3.86, Change: -0.24, Percent Change: -5.85